China Biosimilars Market - Premium Insight, Industry Trends, FPNV Positioning Matrix, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2024 (Q4 2018 Update)

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Stakeholders

2. Research & Forecasting

• 2.1. Research Methodology
  • 2.1.1. Research Instruments
    • 2.1.1.1. Secondary Instrument
    • 2.1.1.2. Primary Instrument
  • 2.1.2. Research Approaches
    • 2.1.2.1. Bottom-up Approach
    • 2.1.2.2. Top-down Approach
  • 2.1.3. Research Reliability & Validity
  • 2.1.4. Research Assumptions
  • 2.1.5. Vendor Inclusion Criteria
• 2.2. Forecasting Methodology
  • 2.2.1. Methodology for Market Estimation & Forecasting
  • 2.2.2. Significance and Importance of the Market Estimation & Forecasting

3. Executive Summary

4. Premium Insight

• 4.1. Market Connectivity
• 4.2. Market Data Feed
• 4.3. Market Vendor Ranking Analysis
• 4.4. Market Dynamics
  • 4.4.1. Drivers
  • 4.4.2. Restraints
  • 4.4.3. Opportunities
  • 4.4.4. Challenges
• 4.5. Porter’s Five Forces Analysis
  • 4.5.1. Threat of New Entrants
  • 4.5.2. Threat of Substitutes
  • 4.5.3. Bargaining Power of Customers
  • 4.5.4. Bargaining Power of Suppliers
  • 4.5.5. Industry Rivalry
• 4.6. CFDA Guidelines

5. China Biosimilars Market, by Indication

• 5.1. Introduction
• 5.2. Autoimmune Diseases
• 5.3. Blood Disorders
• 5.4. Chronic Diseases
• 5.5. Growth Hormone Deficiency
• 5.6. Infectious Diseases
• 5.7. Oncology

6. China Biosimilars Market, by Manufacturing

• 6.1. Introduction
• 6.2. Contract Manufacturing
• 6.3. In-House Manufacturing

7. China Biosimilars Market, by Product

• 7.1. Introduction
• 7.2. Recombinant Glycosylated Proteins
  • 7.2.1. Erythropoietin (EPO)
  • 7.2.2. Follitropin
  • 7.2.3. Monoclonal Antibodies (MABS)
    • 7.2.3.1. Adalimumab
    • 7.2.3.2. Infliximab
    • 7.2.3.3. Rituximab
• 7.3. Recombinant Non-Glycosylated Proteins
  • 7.3.1. Granulocyte Colony-Stimulating Factor (Filgrastim)
  • 7.3.2. Insulin
  • 7.3.3. Interferons
    • 7.3.3.1. Interferon-Alpha
    • 7.3.3.2. Interferon-Beta
  • 7.3.4. Recombinant Human Growth Hormone (RHGH)
• 7.4. Recombinant Peptides
  • 7.4.1. Calcitonin
  • 7.4.2. Glucagon

8. Competitive Strategic Window

• 8.1. Introduction
  • 8.1.1. Leverage Zone
  • 8.1.2. Vantage Zone
  • 8.1.3. Speculative Zone
  • 8.1.4. Bottleneck Zone

9. FPNV Positioning Matrix

• 9.1. Introduction
• 9.2. Scores
  • 9.2.1. Forefront
  • 9.2.2. Pathfinders
  • 9.2.3. Niche
  • 9.2.4. Vital
• 9.3. Business Strategy
• 9.4. Product Satisfaction

10. Competitive News Feed Analysis

11. Company Usability Profiles

• 11.1. 3SBio Inc.
• 11.2. APOGENIX GmbH
• 11.3. AbbVie Inc.
• 11.4. Akeso Biopharma, Inc.
• 11.5. Amgen Inc.
• 11.6. BeiGene Ltd
• 11.7. Biogen Inc.
• 11.8. Bristol-Myers Squibb Pharmaceuticals Limited
• 11.9. Genexine, Inc.,
• 11.10. InflaRx N.V.
• 11.11. Innovent Biologics, Inc.
• 11.12. Janssen Pharmaceuticals, Inc.
• 11.13. Merck Sharp & Dohme Corp.
• 11.14. Pfizer Inc.
• 11.15. Roche Holding AG
• 11.16. Shanghai Junshi Biosciences Co., Ltd.

12. Appendix

• 12.1. Top Reports
• 12.2. Author Details

LIST OF TABLES (11 TABLES)

TABLE 1. CHINA BIOSIMILARS MARKET SIZE, 2016 - 2024 (USD BILLION)

TABLE 2. CHINA BIOSIMILARS MARKET RANKING, BY VENDORS, 2017

TABLE 3. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2016 - 2024 (USD BILLION)

TABLE 4. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2016 - 2024 (USD BILLION)

TABLE 5. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD BILLION)

TABLE 6. 360IRESEARCH SCORES FOR FOREFRONT IN BIOSIMILARS MARKET

TABLE 7. 360IRESEARCH SCORES FOR PATHFINDERS IN BIOSIMILARS MARKET

TABLE 8. 360IRESEARCH SCORES FOR NICHE IN BIOSIMILARS MARKET

TABLE 9. 360IRESEARCH SCORES FOR VITAL IN BIOSIMILARS MARKET

TABLE 10. 360IRESEARCH FPNV POSITIONING MATRIX BUSINESS STRATEGY FOR BIOSIMILARS MARKET

TABLE 11. 360IRESEARCH FPNV POSITIONING MATRIX PRODUCT SATISFACTION FOR BIOSIMILARS MARKET

LIST OF FIGURES (18 TABLES)

FIGURE 1. CHINA BIOSIMILARS MARKET: YEARS CONSIDERED FOR THE STUDY

FIGURE 2. CHINA BIOSIMILARS MARKET: KEY RESEARCH METHODOLOGY

FIGURE 3. CHINA BIOSIMILARS MARKET: KEY RESEARCH INSTRUMENTS

FIGURE 4. CHINA BIOSIMILARS MARKET: KEY SECONDARY INSTRUMENT SOURCES

FIGURE 5. CHINA BIOSIMILARS MARKET: KEY POTENTIAL RESPONDENTS

FIGURE 6. CHINA BIOSIMILARS MARKET: KEY BREAKDOWN OF PRIMARY INSTRUMENT

FIGURE 7. CHINA BIOSIMILARS MARKET: KEY RESEARCH APPROACHES

FIGURE 8. CHINA BIOSIMILARS MARKET: KEY DATA TRIANGULATION

FIGURE 9. CHINA BIOSIMILARS MARKET: KEY RESEARCH ASSUMPTIONS

FIGURE 10. BIOSIMILARS MARKET: KEY MARKET CONNECTIVITY

FIGURE 11. CHINA BIOSIMILARS MARKET SIZE, 2016 - 2024 (USD BILLION)

FIGURE 12. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2017 VS 2024 (USD BILLION)

FIGURE 13. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2017 VS 2024 (USD BILLION)

FIGURE 14. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2017 VS 2024 (USD BILLION)

FIGURE 15. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR CHINA BIOSIMILARS MARKET, BY INDICATION, 2024

FIGURE 16. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR CHINA BIOSIMILARS MARKET, BY MANUFACTURING, 2024

FIGURE 17. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR CHINA BIOSIMILARS MARKET, BY PRODUCT, 2024

FIGURE 18. 360IRESEARCH FPNV POSITIONING MATRIX FOR BIOSIMILARS MARKET